A Mechanistic Pharmacokinetic Model for Liver Transporter Substrates Under Liver Cirrhosis Conditions
Authors:
Open Access
- 1 June 2015
- journal article
- research article
- Published by Wiley in CPT: Pharmacometrics & Systems Pharmacology
- Vol. 4 (6) , 338-349
Abstract
Liver cirrhosis is a disease characterized by the loss of functional liver mass. Physiologically based pharmacokinetic (PBPK) modeling was applied to interpret and predict how the interplay among physiological changes in cirrhosis affects pharmacokinetics. However, previous PBPK models under cirrhotic conditions were developed for permeable cytochrome P450 substrates and do not directly apply to substrates of liver transporters. This study characterizes a PBPK model for liver transporter substrates in relation to the severity of liver cirrhosis. A published PBPK model structure for liver transporter substrates under healthy conditions and the physiological changes for cirrhosis are combined to simulate pharmacokinetics of liver transporter substrates in patients with mild and moderate cirrhosis. The simulated pharmacokinetics under liver cirrhosis reasonably approximate observations. This analysis includes meta-analysis to obtain system-dependent parameters in cirrhosis patients and a top-down approach to improve understanding of the effect of cirrhosis on transporter-mediated drug disposition under cirrhotic conditions.Keywords
This publication has 40 references indexed in Scilit:
- Basic Concepts in Physiologically Based Pharmacokinetic Modeling in Drug Discovery and DevelopmentCPT: Pharmacometrics & Systems Pharmacology, 2013
- A Semi-Mechanistic Model to Predict the Effects of Liver Cirrhosis on Drug ClearanceClinical Pharmacokinetics, 2010
- Liver cirrhosisThe Lancet, 2008
- Physiology-Based Simulations of a Pathological ConditionClinical Pharmacokinetics, 2008
- Multiple Human Isoforms of Drug Transporters Contribute to the Hepatic and Renal Transport of Olmesartan, a Selective Antagonist of the Angiotensin II AT1-ReceptorDrug Metabolism and Disposition, 2007
- Clinical Pharmacology of Bosentan, a Dual Endothelin Receptor AntagonistClinical Pharmacokinetics, 2004
- Influence of Mild Liver Impairment on the Pharmacokinetics and Metabolism of Bosentan, a Dual Endothelin Receptor AntagonistThe Journal of Clinical Pharmacology, 2003
- Single‐Dose Pharmacokinetics of Repaglinide in Subjects with Chronic Liver DiseaseThe Journal of Clinical Pharmacology, 2000
- Effects of Liver Disease on PharmacokineticsClinical Pharmacokinetics, 1999
- Models for describing absorption rate and estimating extent of bioavailability: Application to cefetamet pivoxilJournal of Pharmacokinetics and Biopharmaceutics, 1992